| NCT04461886 |
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I |
https://ClinicalTrials.gov/show/NCT04461886 |
Recruiting |
Nobelpharma |
2022-04-30 |
| NCT03406208 |
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing |
https://ClinicalTrials.gov/show/NCT03406208 |
Recruiting |
Massachusetts General Hospital |
2022-01-30 |
| NCT03820778 |
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 |
https://ClinicalTrials.gov/show/NCT03820778 |
Enrolling by invitation |
Children’s National Research Institute |
2022-07-12 |
| NCT03326388 |
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours |
https://ClinicalTrials.gov/show/NCT03326388 |
Recruiting |
Great Ormond Street Hospital for Children NHS Foundation Trust |
2020-08-31 |
| NCT03310996 |
Non-invasive Stimulation in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT03310996 |
Completed |
University of Manchester |
2018-06-30 |
| NCT03190915 |
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT03190915 |
Recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT03095248 |
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
https://ClinicalTrials.gov/show/NCT03095248 |
Recruiting |
Children’s Hospital Medical Center, Cincinnati |
2021-05-31 |
| NCT03090971 |
Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 |
https://ClinicalTrials.gov/show/NCT03090971 |
Completed |
Fundação Educacional Serra dos Órgãos |
2017-03-23 |
| NCT02964884 |
Interventions for Reading Disabilities in NF1 |
https://ClinicalTrials.gov/show/NCT02964884 |
Recruiting |
Vanderbilt University |
2020-11-30 |
| NCT02944032 |
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT02944032 |
Recruiting |
Children’s National Research Institute |
2020-09-30 |
| NCT02839720 |
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma |
https://ClinicalTrials.gov/show/NCT02839720 |
Recruiting |
National Cancer Institute (NCI) |
2021-12-31 |
| NCT02831257 |
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas |
https://ClinicalTrials.gov/show/NCT02831257 |
Active, not recruiting |
Massachusetts General Hospital |
2020-03-31 |
| NCT02811718 |
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02811718 |
Completed |
Massachusetts General Hospital |
2018-06-30 |
| NCT02728388 |
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II |
https://ClinicalTrials.gov/show/NCT02728388 |
Recruiting |
Medical College of Wisconsin |
2022-08-31 |
| NCT02718131 |
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT02718131 |
Active, not recruiting |
University of Alabama at Birmingham |
2021-05-31 |
| NCT02700230 |
Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02700230 |
Recruiting |
Mayo Clinic |
2021-06-15 |
| NCT02407405 |
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT02407405 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-08-31 |
| NCT02390752 |
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) |
https://ClinicalTrials.gov/show/NCT02390752 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-12-01 |
| NCT02211768 |
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT02211768 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-02-15 |
| NCT02422732 |
Functional Imaging and Reading Deficit in Children With NF1 |
https://ClinicalTrials.gov/show/NCT02422732 |
Completed |
University Hospital, Toulouse |
2015-04-30 |
| NCT02415153 |
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors |
https://ClinicalTrials.gov/show/NCT02415153 |
Active, not recruiting |
National Cancer Institute (NCI) |
2019-07-01 |
| NCT02397967 |
Reading Disability in Children With NF1 |
https://ClinicalTrials.gov/show/NCT02397967 |
Completed |
University Hospital, Toulouse |
2014-04-30 |
| NCT02387177 |
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02387177 |
Completed |
Massachusetts General Hospital |
2017-12-31 |
| NCT02332902 |
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T |
https://ClinicalTrials.gov/show/NCT02332902 |
Completed |
The University of Texas Health Science Center, Houston |
2016-03-31 |
| NCT02298270 |
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype |
https://ClinicalTrials.gov/show/NCT02298270 |
Completed |
Massachusetts General Hospital |
2015-07-31 |
| NCT02246231 |
Effect of Implant Position on Magnetic Resonance Image Distortion |
https://ClinicalTrials.gov/show/NCT02246231 |
Completed |
Manchester University NHS Foundation Trust |
2015-01-31 |
| NCT02129647 |
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT02129647 |
Active, not recruiting |
NYU Langone Health |
2019-02-24 |
| NCT02104323 |
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
https://ClinicalTrials.gov/show/NCT02104323 |
Completed |
Beijing Tiantan Hospital |
2016-04-30 |
| NCT02101736 |
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults |
https://ClinicalTrials.gov/show/NCT02101736 |
Recruiting |
University of Alabama at Birmingham |
2021-05-31 |
| NCT02096471 |
MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 |
https://ClinicalTrials.gov/show/NCT02096471 |
Completed |
University of Alabama at Birmingham |
2017-08-09 |
| NCT01275586 |
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01275586 |
Completed |
Indiana University |
2016-07-31 |
| NCT03871257 |
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma |
https://ClinicalTrials.gov/show/NCT03871257 |
Recruiting |
National Cancer Institute (NCI) |
2027-05-01 |
| NCT01968590 |
Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT01968590 |
Recruiting |
University of Utah |
2022-10-31 |
| NCT01851135 |
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT01851135 |
Completed |
Nantes University Hospital |
2016-04-30 |
| NCT01767792 |
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT01767792 |
Active, not recruiting |
University of Alabama at Birmingham |
2019-04-30 |
| NCT01682811 |
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) |
https://ClinicalTrials.gov/show/NCT01682811 |
Completed |
Medical College of Wisconsin |
2016-10-31 |
| NCT01633008 |
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain |
https://ClinicalTrials.gov/show/NCT01633008 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-05-01 |
| NCT01490476 |
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients |
https://ClinicalTrials.gov/show/NCT01490476 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2016-04-30 |
| NCT01419639 |
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 |
https://ClinicalTrials.gov/show/NCT01419639 |
Completed |
NYU Langone Health |
2012-12-31 |
| NCT01412892 |
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01412892 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2013-10-31 |
| NCT01345136 |
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma |
https://ClinicalTrials.gov/show/NCT01345136 |
Active, not recruiting |
Jonsson Comprehensive Cancer Center |
2021-02-01 |
| NCT04283669 |
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
https://ClinicalTrials.gov/show/NCT04283669 |
Active, not recruiting |
University of Alabama at Birmingham |
2025-08-18 |
| NCT04201457 |
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration |
https://ClinicalTrials.gov/show/NCT04201457 |
Recruiting |
Pediatric Brain Tumor Consortium |
2025-02-28 |
| NCT04085159 |
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis |
https://ClinicalTrials.gov/show/NCT04085159 |
Recruiting |
Shenzhen Geno-Immune Medical Institute |
2021-01-31 |
| NCT03981510 |
Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation |
https://ClinicalTrials.gov/show/NCT03981510 |
Recruiting |
University of Aarhus |
2023-12-31 |
| NCT03975829 |
Pediatric Long-Term Follow-up and Rollover Study |
https://ClinicalTrials.gov/show/NCT03975829 |
Recruiting |
Novartis |
2022-12-23 |
| NCT03962543 |
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT03962543 |
Recruiting |
SpringWorks Therapeutics, Inc. |
2022-07-31 |
| NCT03888248 |
Whole-body Vibration in Children With Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT03888248 |
Enrolling by invitation |
Manchester University NHS Foundation Trust |
2020-07-31 |
| NCT03873610 |
Resiliency Training in Adolescents With NF1 and NF2 |
https://ClinicalTrials.gov/show/NCT03873610 |
Recruiting |
Massachusetts General Hospital |
2022-04-01 |
| NCT03826940 |
From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 |
https://ClinicalTrials.gov/show/NCT03826940 |
Recruiting |
University of Coimbra |
2020-01-31 |
| NCT03741101 |
Treatment of NF1-related Plexiform Neurofibroma With Trametinib |
https://ClinicalTrials.gov/show/NCT03741101 |
Recruiting |
Region Skane |
2022-07-31 |
| NCT03688568 |
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors |
https://ClinicalTrials.gov/show/NCT03688568 |
Recruiting |
Indiana University |
2020-09-01 |
| NCT03672838 |
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2) |
https://ClinicalTrials.gov/show/NCT03672838 |
Recruiting |
NYU Langone Health |
2020-06-30 |
| NCT03649165 |
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants |
https://ClinicalTrials.gov/show/NCT03649165 |
Completed |
AstraZeneca |
2018-10-21 |
| NCT03531814 |
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials |
https://ClinicalTrials.gov/show/NCT03531814 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-09-30 |
| NCT03433183 |
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors |
https://ClinicalTrials.gov/show/NCT03433183 |
Recruiting |
Sarcoma Alliance for Research through Collaboration |
2021-09-30 |
| NCT01207687 |
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) |
https://ClinicalTrials.gov/show/NCT01207687 |
Completed |
National Cancer Institute (NCI) |
2013-02-28 |
| NCT01140360 |
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01140360 |
Completed |
Indiana University |
2016-08-31 |
| NCT01125046 |
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas |
https://ClinicalTrials.gov/show/NCT01125046 |
Active, not recruiting |
Northwestern University |
2019-07-31 |
| NCT01089101 |
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma |
https://ClinicalTrials.gov/show/NCT01089101 |
Recruiting |
National Cancer Institute (NCI) |
2022-12-31 |
| NCT01058330 |
Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 |
https://ClinicalTrials.gov/show/NCT01058330 |
Completed |
Shriners Hospitals for Children |
2014-02-28 |
| NCT01031901 |
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) |
https://ClinicalTrials.gov/show/NCT01031901 |
Completed |
The University of Texas Health Science Center, Houston |
2011-02-28 |
| NCT00973739 |
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
https://ClinicalTrials.gov/show/NCT00973739 |
Completed |
NYU Langone Health |
2012-10-31 |
| NCT00901849 |
Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1) |
https://ClinicalTrials.gov/show/NCT00901849 |
Completed |
Children’s National Research Institute |
2010-07-31 |
| NCT00865644 |
Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00865644 |
Completed |
Massachusetts General Hospital |
2010-04-30 |
| NCT00853580 |
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 |
https://ClinicalTrials.gov/show/NCT00853580 |
Completed |
University of Alabama at Birmingham |
2014-05-31 |
| NCT01553149 |
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma |
https://ClinicalTrials.gov/show/NCT01553149 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-06-30 |
| NCT01673009 |
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT01673009 |
Completed |
Indiana University |
2011-12-31 |
| NCT01362803 |
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors |
https://ClinicalTrials.gov/show/NCT01362803 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2019-03-29 |
| NCT03231306 |
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT03231306 |
Recruiting |
University of Alabama at Birmingham |
2022-12-31 |
| NCT02471339 |
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain |
https://ClinicalTrials.gov/show/NCT02471339 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-04-30 |
| NCT00754780 |
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00754780 |
Completed |
Mayo Clinic |
2004-08-31 |
| NCT00727233 |
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00727233 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-06-16 |
| NCT00657202 |
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 |
https://ClinicalTrials.gov/show/NCT00657202 |
Completed |
Massachusetts General Hospital |
2009-10-31 |
| NCT00634270 |
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00634270 |
Completed |
University of Alabama at Birmingham |
2014-11-30 |
| NCT00624234 |
Neurobiology and Treatment of Reading Disability in NF-1 |
https://ClinicalTrials.gov/show/NCT00624234 |
Completed |
Vanderbilt University |
2013-03-31 |
| NCT00589784 |
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma |
https://ClinicalTrials.gov/show/NCT00589784 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-10-31 |
| NCT00352599 |
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) |
https://ClinicalTrials.gov/show/NCT00352599 |
Completed |
University of California, Los Angeles |
2014-03-31 |
| NCT00352495 |
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma |
https://ClinicalTrials.gov/show/NCT00352495 |
Completed |
Children’s Oncology Group |
2011-09-30 |
| NCT00304083 |
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors |
https://ClinicalTrials.gov/show/NCT00304083 |
Completed |
Sarcoma Alliance for Research through Collaboration |
2014-06-30 |
| NCT00169611 |
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate |
https://ClinicalTrials.gov/show/NCT00169611 |
Completed |
Hospices Civils de Lyon |
2011-01-31 |
| NCT00076102 |
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00076102 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-04-01 |
| NCT00053937 |
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00053937 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00030264 |
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00030264 |
Completed |
Children’s Hospital of Philadelphia |
2013-12-31 |
| NCT00030043 |
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors |
https://ClinicalTrials.gov/show/NCT00030043 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00021541 |
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas |
https://ClinicalTrials.gov/show/NCT00021541 |
Completed |
National Institutes of Health Clinical Center (CC) |
2009-02-19 |
| NCT00004437 |
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 |
https://ClinicalTrials.gov/show/NCT00004437 |
Completed |
FDA Office of Orphan Products Development |
NA |